Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center  

作　　者：Wagner Eduardo Cruz-Diaz Victor Paitan Jersinho Medina Raymundo Flores Juan Haro-Varas Raul Mantilla Victor Castro-Oliden 

机构地区：[1]Department of Oncology,Instituto Nacional de Enfermedades Neoplásicas,Lima 15038,Perú [2]Department of Pathology,Instituto Nacional de Enfermedades Neoplásicas,Lima 15038,Perú [3]Department of Radiology,Instituto Nacional de Enfermedades Neoplásicas,Lima 15038,Perú

出　　处：《World Journal of Gastrointestinal Oncology》2024年第12期4675-4684,共10页世界胃肠肿瘤学杂志（英文）

摘　　要：BACKGROUND Numerous studies have indicated that the temozolomide and capecitabine regimen(TEMCAP)exhibits a certain level of efficacy in treating advanced,welldifferentiated gastroenteropancreatic neuroendocrine tumors(GEP-NET).However,published data from Peru are limited.We hypothesize that this regimen could be a viable therapeutic option for advanced GEP-NET in the Peruvian population.AIM To evaluate overall survival(OS)in patients diagnosed with advanced GEP-NET treated with TEMCAP at the Instituto Nacional de Enfermedades Neoplásicas(INEN)in Lima-Perú.METHODS A retrospective review was conducted to identify patients with GEP-NEN treated with the TEMCAP regimen between 2011 and 2021 at the INEN.A total of thirtyeight patients were included in the final analysis:Thirty-five received TEMCAP as a first-line treatment,and three as a second-line treatment.The primary objective was to evaluate OS.The efficacy and safety of TEMCAP were assessed until the occurrence of unacceptable toxicity or disease progression.Survival outcomes were estimated using the Kaplan-Meier method.RESULTS The median age of the patients was 52 years(range 24-77 years),and 53.3%were female.The most common symptoms at diagnosis were abdominal pain in 31 patients(81.6%).Primary tumors included 12 in the rectum(31.6%),11 in the pancreas(28.9%),3 in the ileum(7.9%),2 in the mesentery(5.3%),2 in the small intestine(5.3%),1 in the appendix(2.6%),1 in the stomach(2.6%)and 6 cases of liver metastasis of unknown primary(15.8%).Five were neuroendocrine tumors(NET)G1(13.2%),33 were NET G2(86.8%),five had Ki67<3%(13.2%),and 33 had Ki67 between 3%and 20%(86.8%).TEMCAP was administered to 35(92.1%)patients as first-line treatment.OS at 12,36,and 60 months was estimated in 80%,66%,and 42%,respectively,with a median OS of 49 months.CONCLUSION TEMCAP therapy is a viable first-line option regarding efficacy and tolerability in areas where standard therapy is inaccessible.

关 键 词：WELL-DIFFERENTIATED Gastroenteropancreatic neuroendocrine tumors CAPECITABINE TEMOZOLOMIDE Retrospective study Treatment CHEMOTHERAPY 

分 类 号：R735.2[医药卫生—肿瘤]